EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort

Guillermo Ruiz-Irastorza iD, Diana Paredes-Ruiz iD, Maria Herrero-Galvan, Victor Moreno-Torres iD, Halbert Hernandez-Negrin iD, Ioana Ruiz-Arruza iD, Cedric Leonard, Christophe Richez iD, Estibaliz Lazaro iD

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25334 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Guillermo Ruiz-Irastorza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biobizkaia Health Research Institute and University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Methylprednisolone, Remission Induction, Propensity Score. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hezkuntza Saila, Eusko Jaurlaritza, Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía-Sevilla, Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation.

Methods

We conducted an observational study of routine clinical care data from the Lupus‐Cruces‐Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: 12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed.

Results

Two hundred thirty‐three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS‐adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04–623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27–21.97, P = 0.022) and moderate‐severe SLE activity (adjusted OR 4.07, 95% CI 1.11–14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer‐term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone.

Conclusion

This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicMethylprednisoloneRemission InductionPropensity ScoreHumansFemaleMaleAdultMiddle AgedTreatment OutcomeLongitudinal StudiesGlucocorticoidsTime FactorsSeverity of Illness IndexPulse Therapy, DrugFrance

Substanzen

MethylprednisoloneGlucocorticoids

Autor:innen und Institutionen

  • Biobizkaia Health Research Institute and University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain.
  • Biobizkaia Health Research Institute, Bizkaia, Basque Country, Spain.
  • University of The Basque Country-UPV/EHU, Bizkaia, Basque Country, Spain.
  • Hospital Universitario Cruces, Bizkaia, Basque Country, UNIR Health Sciences School and Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Hospital Universitario Cruces, Bizkaia, Basque Country, Hospital Regional Universitario de Málaga and Universidad de Málaga, Málaga, Spain.
  • Bordeaux Hospital University, Bordeaux, France.

ORCID-Profile: Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Victor Moreno-Torres, Halbert Hernandez-Negrin, Ioana Ruiz-Arruza, Christophe Richez, Estibaliz Lazaro

Förderung

  • Hezkuntza Saila, Eusko Jaurlaritza
  • Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía-Sevilla
  • Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
  • Consejería de Transformación Económica, Industria, Conocimiento y Universidades

Zitieren

APA

Ruiz-Irastorza, G., Paredes-Ruiz, D., Herrero-Galvan, M., Moreno-Torres, V., Hernandez-Negrin, H., Ruiz-Arruza, I., Leonard, C., Richez, C., & Lazaro, E. (2024). Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort. Arthritis Care & Research. https://doi.org/10.1002/acr.25334

Vancouver

Ruiz-Irastorza G, Paredes-Ruiz D, Herrero-Galvan M, Moreno-Torres V, Hernandez-Negrin H, Ruiz-Arruza I, et al. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort. Arthritis Care & Research. 2024. doi:10.1002/acr.25334

BibTeX
@article{RuizIrastorza2024,
  author = {Ruiz-Irastorza, Guillermo and Paredes-Ruiz, Diana and Herrero-Galvan, Maria and Moreno-Torres, Victor and Hernandez-Negrin, Halbert and Ruiz-Arruza, Ioana and Leonard, Cedric and Richez, Christophe and Lazaro, Estibaliz},
  title = {Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus‐Cruces‐Bordeaux Inception Cohort},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25334}
}
Kostenlos starten →